News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mesoblast Limited Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy



6/26/2013 9:34:45 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Melbourne, Australia; 26 June 2013 and New York, USA; 25 June 2013: Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has received approvals from Australian ethics committees to commence a Phase 2 trial evaluating a single intravenous infusion of its proprietary allogeneic or “off-the-shelf” adult Mesenchymal Precursor Cells (MPCs) in patients with type 2 diabetes and advanced kidney disease, or diabetic nephropathy.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES